Abstract: The present invention provides a method for detecting and grading benign and malignant tumors using at least one sensor of conductive nanoparticles capped with an organic coating in conjunction with a learning and pattern recognition algorithm. The method utilizes a plurality of response induced parameters to obtain improved sensitivity and selectivity for diagnosis, prognosis, monitoring and staging various types of cancers, or for identifying or grading benign or malignant tumors.

Abstract: A method and a kit for the prevention of venous stenosis associated with the use of hemodialysis AV shunts. The kit may use a bifurcated needle for providing access to the shunt or blood vessel. One of the arms is used for returning the blood to the subject after dialysis treatment, while the other arm is used for inserting a device for cleaning the vein, the device being either an autonomous crawling device, or a passive tethered device moved down the vein by the blood flow. The autonomous crawling device may be a series of sequentially inflatable chambers, the stenosis being cleared by pressure from the outer walls of the chambers when inflated and moved. The passive device may be an element having a flexible disc-like structure, whose flexible peripheral edge slides along the inner walls of the blood vessel, compressing or clearing the material attached thereto.

Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a structure of wherein Z is aryl or substituted aryl, heteroaryl, or substituted heteroaryl; X is —S—, —S(O)—, or S(O)2—; R20 and R21 are each independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, or halogenated alkyl; one of R22, R23, and R24 is —O— and the others of R22, R23 and R24 are independently —CH2—, or —C(R13)— wherein R13 is alkyl, alkenyl, alkynyl, trialkylsilyl group, or —(CH2)mOR15, wherein R15 is alkyl or an aryl and m is an integer in the range of 1 to 10; and R25 is H, alkyl, substituted alkyl, halogen, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, C1-C3 alkoxy, aryloxy, or —(CH2)qOR17, wherein R17 is alkyl an aryl and q is an integer in the range of 1 to 10.

Abstract: A composition, apparatuses and a methods for collecting and detecting compounds, including but not limited to volatile organic compounds, in a human breath sample are provided. In some embodiments, there is provided a glass-wool matrix and a sorbent material distributed throughout the glass-wool matrix.

Abstract: A method and a system for generating adaptive fast forward of egocentric videos are provided here. The method may include the following steps: obtaining a video footage containing a sequence of image frames captured by a non-stationary capturing device; estimating a moving direction of the non-stationary capturing device for a plurality of frames in the sequence of image frames; and generating a shortened video footage having fewer frames than said video footage, by sampling the sequence of image frames, wherein the sampling is carried out by selecting specific image frames and that minimize an overall cost associated with a deviation from a specific direction related to the moving direction, calculated for each of said plurality of image frames.

Abstract: Methods for treating or preventing tauopathies and/or A? amyloidosis by modulating CRF receptor signaling. Accumulation of hyperphosphorlyated tau protein in the CNS may be reduced by administration of CRF-R1 selective antagonists and/or CRF-R2 selective agonists. For example, in some aspects, methods for preventing the onset of Alzheimer's disease by administration of CRF-R1 selective antagonist are provided.

Abstract: An isolated nucleic acid agent is disclosed comprising a nucleic acid sequence which downregulates expression of a gene product of a Varroa destructor mite. Compositions comprising same and uses thereof are also disclosed.

Abstract: The present invention provides a liposome based composition wherein the liposome includes a peptide conjugated thereto via a peptide bond, wherein the peptide includes a spacer amino acid and a short Apolipoprotein E recognition sequence or a short Amyloid beta recognition sequence. This invention further provides a process for making the liposome and methods of utilizing the liposome based composition for therapeutic and diagnostic purposes.

Abstract: Apparatuses and methods for controlling ionic strength and/or pH of a solution are provided.

Abstract: The present invention provides a microfluidic device which includes at least 3 chambers, a chamber inlet, at least 2 dichotomously branching generations of channels, a channel inlet, and a channel outlet, wherein the channels and the chambers are separated by deformable walls, wherein each wall is lined with at least one cavity, and wherein the cavity is fluidly connected to the channel.

Abstract: Systems, kits and methods for non-invasive, long-term, real-time monitoring of one or more physiological parameters of a cell, including but not limited to oxygen uptake, are provided.

Abstract: A paper-based micro fluidic device suitable for electrokinetics and particularly isotachophoresis (ITP) and a kit comprising same is provided. Further, a method for the preparation of said paper-based micro fluidic device and a method of use thereof for the detection and/or separation of molecules of interest are provided.

Abstract: Disclosed are variant RTEF-1 polypeptides having an RTEF-1 amino acid sequence with one or more internal deletions, wherein the polypeptides reduce VEGF promoter activity. Some of the RTEF-1 polypeptides include an amino acid sequence that is at least 80% identical to the contiguous amino acids of 1) amino acids 24 to 47 of SEQ ID NO:15 and 2) each of SEQ ID NOs:16 and 17, but does not comprise the contiguous amino acids of SEQ ID NOs:8, 9, 11, or 12. Also disclosed are nucleic acids encoding the variant RTEF-1 polypeptides of the present invention. Pharmaceutical compositions that include the polypeptides and nucleic acids of the present invention are also disclosed. Methods of inducing cell contact inhibition, regulating organ size, and reducing intracellular YAP activity are also set forth, as well as methods of treating hyperproliferative diseases such as cancer using the pharmaceutical compositions of the present invention.

Abstract: The present invention discloses composition and methods for reducing the weight loss and/or preserving the natural gloss of post-harvest edible plant matter. In particular, the methods comprising applying to the surface of the plant matter a composition comprising an edible wax having a melting temperature below 70° C.; a hydrocolloid; a fatty acid; an emulsifier; and water, wherein said edible wax is present in a weight percent ranging from about 10% to about 25% of the total weight of the composition.

Abstract: According to an aspect of some embodiments of the present invention there is provided a method for converting energy. The method comprises receiving energy from an external source, using the received energy for inducing a mass exchange process to release thermodynamic energy, and converting the thermodynamic energy directly into electrical energy at sufficient amount for performing work therewith. In some embodiments of the present invention, a portion of the released energy is converted to a pressure wave, and the mechanical energy constituted by the pressure wave is converted to non-mechanical energy.

Abstract: The invention relates to devices and methods which implement a reconfigurable network-on-a-chip (NoC) multiple-input-multiple-output (MIMO) orthogonal frequency division multiplexing (OFDM) application specific integrated circuit (ASIC) architecture which fully implements a 4×4 MIMO OFDM receiver and transmitter, which has a radiation hardened phase-locked loop (PLL) that provides a 1 GHz or 500 MHz clock to a NoC switch fabric, and at least two NoC Clusters on said NoC switch fabric, an Up/Down conversion cluster and a main MIMO OFDM and Single Carrier system cluster.

Abstract: Compositions comprising liposomes composed of whole cell membrane fraction are provided. The liposomes may be attached to, or encapsulate a pharmaceutical agent. Also provided are methods of generating and using these liposomes.

Abstract: A configuration arrangement includes a first interface configured to receive configuration information from a master configuration function and a second interface configured to provide at least one output to one or more entities to be configured. Configuration circuitry operates responsive to the configuration information to provide the at least one output, wherein that output controls the configuration of the one or more entities.

Abstract: Embodiments of the invention relate to methods of treatment a cardiovascular disease in a patient comprising administering an effective amount of a statin or a pharmaceutically acceptable salt thereof in combination with an effective amount of a transition metal complex of a corrole, an optically active isomer thereof or a pharmaceutically acceptable salt thereof. Further embodiments refer to pharmaceutical compositions comprising a statin and a corrole. Optionally, the corrole has a structure: wherein; M is a transition metal selected from the group consisting of Mn, Fe, Ru, Co, V, Cr, and Cu and R1, R2, R3, X1, X2, X3X4; E2, E3, E17 and E18 are each defined as in the specification.

Abstract: The present invention provides a composite comprising at least one hydrophobic organic compound and a matrix of at least one metal; wherein said at least one hydrophobic compound is entrapped within said matrix, compositions comprising at least one composite and methods of its preparation.